Even as the global diabetes war continues to rage, Indian pharmaceutical companies are emerging from the shadows, armed with an arsenal of innovative drugs and therapies. Several homegrown giants are not only tackling the diabetes crisis within the country, but also making waves on the international stage, reports The Pharma Letter’s India correspondent.
From pioneering research to strategic alliances with Big Pharma, Indian companies are bent on rewriting the rules of the game. Lupin (BOM: 500257), which strengthened its diabetes portfolio by acquiring Huminsulin in India from Eli Lilly (NYSE: LLY), to Zydus Lifesciences (BOM: 532321), with its recent launch of Sitaglyn and Siglyn for the management of type 2 diabetes, as well as its partnership with CVS Caremark to add its sitagliptin-based diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to the CVS Caremark formulary starting January 1 -- are shiny examples.
Cipla's (BOM: 500087) launch of Afrezza, India's first inhalable insulin, is another case in point. Cipla launched India's first inhalable insulin after receiving approval from the Central Drugs Standard Control Organization (CDSCO). Afrezza, developed by MannKind Corporation in the USA, is a needle-free, rapid-acting insulin that offers a convenient alternative for managing both type 1 and type 2 diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze